<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474603</url>
  </required_header>
  <id_info>
    <org_study_id>IMPEDE-DM2</org_study_id>
    <nct_id>NCT01474603</nct_id>
  </id_info>
  <brief_title>Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients</brief_title>
  <acronym>IMPEDE-DM2</acronym>
  <official_title>IMpact of n-3 Polyunsaturated Fatty Acids With a Protein-Enriched DiEt With Low Glycemic Index on Metabolic and Inflammatory Parameters in Type 2 Diabetic and Obese Patients: an Observational Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enervit Spa (company)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is tightly associated with overweight and obesity. Inflammatory processes are
      crucial triggers for insulin resistance that paves the way to type 2 diabetes. In a previous
      study the investigators have shown that n-3 polyunsaturated fatty acids diminish adipose
      tissue inflammation in morbidly obese non-diabetic subjects. in this observational study the
      investigators will apply n-3 polyunsaturated fatty acids as addition to a protein-enriched
      diet with low glycemic index to overweight and obese patients with insulin resistance,
      prediabetes and manifest type 2 diabetes over up to 6 months. Primary efficacy parameters are
      changes from baseline in HbA1c and body weight for for type 2 diabetes and all other
      patients, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change from baseline (type 2 diabetes patients)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>body weight change from baseline (non-diabetic patients)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline of inflammatory and metabolic parameters</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Overweight</condition>
  <condition>Obese</condition>
  <condition>Insulin Resistance</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>overweight or obese diabetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>n-3 PUFA in protein-enriched low-GI diet</intervention_name>
    <description>3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma samples for biochemical analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        overweight to obese insulin resistant, prediabetic and diabetic patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight or obesity AND

          -  insulin resistant OR pre-diabetes OR type 2 diabetes

        Exclusion Criteria:

          -  changes in anti-diabetic medication in the lat two months

          -  acute illness during the last two weeks

          -  HIV infection

          -  hepatitis of other clinically significant hepatic disease other than non-alcoholic
             hepatic steatosis

          -  severe or insufficiently treated cardiovascular, renal (GFR-MDRD &lt; 60 ml/min) or
             pulmonary disease

          -  Macroproteinuria (&gt; 300 mg/g creatinine)

          -  clinically significant or insufficiently treated thyroid disease

          -  anemia

          -  active malignant disease

          -  inborn or acquired coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. Medicine III, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas M Stulnig</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

